Smith & Nephew

OverviewSuggest Edit

Smith & Nephew is a medical technology company. It operates in three main segments: Orthopaedic Reconstruction and Trauma, Endoscopy and Advanced Wound Management. The company offers sports medicine joint repair products for surgeons, arthroscopic enabling technologies for healthcare providers, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, electromechanical and mechanical tissue resection devices, etc. 

TypePublic
Founded1856
HQTN, US
Websitesmith-nephew.com
Employee Ratings3.9
Overall CultureB

Latest Updates

Employees (est.) (Dec 2017)15,000
Job Openings1,071
Revenue (FY, 2021)$5.2 B(+15%)
Share Price (May 2022)£13(+3%)
Cybersecurity ratingDMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Smith & Nephew

Roland Diggelmann

Roland Diggelmann

Chief Executive Officer and Director
Brad Cannon

Brad Cannon

President Orthopaedics, Sports Medicine and ENT and Americas
Anne-Françoise Nesmes

Anne-Françoise Nesmes

Chief Financial Officer and Director
Elga Lohler

Elga Lohler

Chief Human Resources Officer
Helen Barraclough

Helen Barraclough

Group General Counsel
Erik Engstrom

Erik Engstrom

Independent Non-Executive Director
Show more

Smith & Nephew Office Locations

Smith & Nephew has offices in Andover, Austin, Durham, Fort Worth and in 2 other locations
São Paulo, BR
Av. do Café, 277
Andover, MA, US
150 Minuteman Rd
Austin, TX, US
7000 W William Cannon Dr
Durham, NC, US
Carlisle Place, 4721 Emperor Blvd #100
Fort Worth, TX, US
3909 Hulen St
Saint Petersburg, FL, US
970 Lake Carillon Dr #110
Show all (7)

Smith & Nephew Financials and Metrics

Smith & Nephew Revenue

Smith & Nephew's revenue was reported to be $5.21 b in FY, 2021
USD

Revenue (FY, 2021)

5.2b

Gross profit (FY, 2021)

4.2b

Net income (FY, 2021)

524.0m

EBITDA (FY, 2021)

1.3b

EBIT (FY, 2021)

677.0m

Market capitalization (3-May-2022)

11.5b

Closing stock price (3-May-2022)

13.0

Cash (31-Dec-2021)

1.3b

EV

13.5b
Smith & Nephew's current market capitalization is £11.5 b.
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

4.9b5.1b4.6b5.2b

Cost of goods sold

(863.0m)(836.0m)(834.0m)(977.0m)

Gross profit

4.0b4.3b3.7b4.2b

R&D expense

(246.0m)(292.0m)(307.0m)(356.0m)
Half Year
USDH1, 2019H1, 2020H1, 2021

Revenue

2.5b2.0b2.6b

Cost of goods sold

(400.0m)(375.0m)(512.0m)

Gross profit

2.1b1.7b2.1b

R&D expense

(139.0m)(148.0m)(171.0m)
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Cash

365.0m277.0m1.8b1.3b

Accounts Receivable

1.1b1.1b911.0m971.0m

Prepaid Expenses

69.0m96.0m176.0m185.0m

Inventories

1.4b1.6b1.7b1.8b
Half Year
USDH1, 2019H1, 2020H1, 2021

Cash

137.0m347.0m1.4b

Accounts Receivable

1.3b1.2b1.3b

Inventories

1.5b1.7b1.8b
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

781.0m743.0m246.0m586.0m

Depreciation and Amortization

435.0m502.0m562.0m567.0m

Inventories

(152.0m)(204.0m)(45.0m)(151.0m)

Accounts Payable

71.0m201.0m(103.0m)82.0m
Half Year
USDH1, 2019H1, 2020H1, 2021

Net Income

383.0m(34.0m)223.0m

Depreciation and Amortization

248.0m271.0m294.0m
USDFY, 2018

EV/EBITDA

0.9 x

EV/EBIT

1.3 x

EV/CFO

1.2 x
Show all financial metrics

Smith & Nephew Operating Metrics

Smith & Nephew's Training Provided, no. of people was reported to be 90 k in FY, 2016.
FY, 2016

Training Provided, no. of people

90 k

Smith & Nephew Acquisitions / Subsidiaries

Company NameDateDeal Size
Integra LifeSciencesSeptember 29, 2020$240 m
Osiris TherapeuticsMarch 15, 2019$600 m

Smith & Nephew Revenue Breakdown

Embed Graph

Smith & Nephew revenue breakdown by business segment: 20.7% from ORTHOPAEDICS, 14.4% from ADVANCED WOUND MANAGEMENT, 15.0% from SPORTS MEDICINE & ENT, 8.0% from SPORTS MEDICINE JOINT REPAIR, 5.7% from ARTHROSCOPIC ENABLING TECHNOLOGIES, 5.5% from TRAUMA & EXTREMITIES, 8.4% from KNEE IMPLANTS, 5.9% from HIP IMPLANTS, 7.0% from ADVANCED WOUND CARE and 9.5% from Other

Smith & Nephew Cybersecurity Score

Cybersecurity ratingPremium dataset

D

69/100

SecurityScorecard logo

Smith & Nephew Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Smith & Nephew Online and Social Media Presence

Embed Graph

Smith & Nephew Company Culture

  • Overall Culture

    B

    72/100

  • CEO Rating

    A-

    76/100

  • Compensation

    A+

    80/100

  • Diversity

    A-

    76/100

Learn more on Comparably

Smith & Nephew News and Updates

Insights on the Lymphedema Treatment Global Market to 2028 - Featuring Bio Compression, Tactile Medical and Smith & Nephew Among Others

Dublin, March 01, 2022 (GLOBE NEWSWIRE) -- The "Lymphedema Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Condition Type, Treatment Type, and End-User" report has been added to ResearchAndMarkets.com's offering. The lymphedema treatment market is projected to reach US…

Global Soft Tissue Repair Market Insights 2021-2028 Featuring Profiles of Key Players, Including Smith & Nephew, DePuy Synthes, Arthrex, Medtronic, and Integra Life Sciences Corp

Dublin, Dec. 13, 2021 (GLOBE NEWSWIRE) -- The "Soft Tissue Repair Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product; Application; and Geography" report has been added to ResearchAndMarkets.com's offering. The global soft tissue repair market is expected to reach US$ 13,646.7…

Global Negative Pressure Wound Therapy Technology Devices Market 2021, Featuring 3M, Baymax Research, Cardinal Health, ConvTec Group, Medela and Smith & Nephew

Dublin, Dec. 10, 2021 (GLOBE NEWSWIRE) -- The "Global Negative Pressure Wound Therapy Technology Devices, 2021: Frost Radar Report" report has been added to ResearchAndMarkets.com's offering.

Global $10.3 Billion Sports Medicine Technologies and Markets to 2026 Featuring Anika Therapeutics, Bioventus, DePuy Synthes, Emcyte, Medtronic, Orthofix, Smith & Nephew, and Stryker

Dublin, Nov. 08, 2021 (GLOBE NEWSWIRE) -- The "Sports Medicine: Technologies and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Global Surgical Robots Industry 2021-2027 Featuring Profiles of Leading Players Smith & Nephew, Mazor Robotics, Auris Health, and SRI Int'l Among Others

Dublin, Oct. 18, 2021 (GLOBE NEWSWIRE) -- The "Surgical Robots Market based on Product and Service, Application, End User, and Geography-Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Global Sports Medicine Market to Cross $12 Billion by 2027 | Industry Analysis & Competition Insights of Zimmer Biomet, Medtronic, Smith & Nephew, and Stryker

Dublin, Oct. 05, 2021 (GLOBE NEWSWIRE) -- The "Sports Medicine Market, Global Forecast, Impact of COVID-19, Industry Trends, by Product Type, Growth, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
Show more

Smith & Nephew Frequently Asked Questions

  • When was Smith & Nephew founded?

    Smith & Nephew was founded in 1856.

  • Who are Smith & Nephew key executives?

    Smith & Nephew's key executives are Roland Diggelmann, Brad Cannon and Anne-Françoise Nesmes.

  • How many employees does Smith & Nephew have?

    Smith & Nephew has 15,000 employees.

  • What is Smith & Nephew revenue?

    Latest Smith & Nephew annual revenue is $5.2 b.

  • What is Smith & Nephew revenue per employee?

    Latest Smith & Nephew revenue per employee is $347.5 k.

  • Who are Smith & Nephew competitors?

    Competitors of Smith & Nephew include DePuy Synthes, Zimmer Biomet and Integer Holdings.

  • Where are Smith & Nephew offices?

    Smith & Nephew has offices in Andover, Austin, Durham, Fort Worth and in 2 other locations.

  • How many offices does Smith & Nephew have?

    Smith & Nephew has 7 offices.